Mickey and Minnie must be very happy

Mickey and Minnie must be very happy

One of the most under-appreciated jobs in medical research is performed not by humans but by rats and mice. Yes it’s a fair statement to say that without these wonderful rodents we wouldn’t get very far and that drug development would likely come to a screeching halt or at minimum slow to a crawl. However, there are days when humans bring nothing but joy and celebration to the rodent world with today being one of those days.

According to press release issued by Diamyd Medical; “A recent paper (Tian, Dang, Kaufman, et al. Diabetes 2014;63:3128–3134) reports that newly diabetic NOD mice have successfully been treated and some even cured using a combination regimen consisting of GABA and Antigen Based Therapy (ABT). The ABT used in the study was pro-insulin formulated in alum, while similar results were obtained with GAD65 in alum as the ABT in a previous paper using an islet transplantation NOD model (Tian, Dang, Kaufman. PLoS One 2011;6:e25337). GAD65 is the active substance in Diamyd®, the Company’s ABT which is currently being tested in children for the treatment and prevention of type 1 diabetes.”

This news was instantly picked by the diabetes blogging community hailing this as a major advancement in diabetes research.

Now Diabetic Investor hates to burst anyone’s bubble but this is not the first nor will it be the last time some company comes along and says they have “cured” diabetes in mice or rats. While this is great news for Mickey and Minnie, it’s hardly news for the millions of patients with diabetes; at least not for years if ever. Honestly we can’t express our outrage strong enough when companies like Diamyd through around the word cure when they haven’t proved anything expect they cured some mice with a therapy option that is years away from commercialization and may never see the light of day.

We all know why they do this, money. When it comes to raising money companies with early stage drugs or devices aren’t shy when it comes to laying it on pretty thick. Al Mann, the founder and CEO of MannKind (NASDAQ:MNKD) is perhaps the best ever at selling snake oil and proved it completely as he got Sanofi (NYSE:SNY) to invest nearly a billion bucks in MannKind for product whose sales potential is maybe a few hundred million. But Al isn’t the only example of how large companies aren’t immune to overtly stupid acts, as GE, yes that company that brings good things to light, was duped out of $8 million by the now defunct C8 MediSensors. And let’s not forget the millions, perhaps billions, invested in the biggest diabetes scam of all – a non-invasive glucose monitor.

Let’s be clear here Diabetic Investor is in no way implying that the folks at Diamyd are by any means crooks. We’re sure they believe the manure they are spreading and who knows something good just might grow here. Still Diabetic Investor has been around the block and knows that one of the best sayings ever is – A company can steal more money with a good PowerPoint presentation then they can with a gun.

Wonder where the folks at Diamyd will be say 10 years from now, will they be Noble Prize winners for curing diabetes or laughing all the way to the bank?

Well at least Mickey and Minnie can rest easy.